1. New Oral AnticoagulantsWho Gets What for Atrial Fibrillation andVenous Thromboembolism?Kathryn Hassell, MDProfessor of Medicine, Division of HematologyUniversity of Colorado…

1. NOACs Dr Carolyn Grove Clinical and Laboratory Haematologist Sir Charles Gairdner Hospital and PathWest Laboratory Medicine 2. Overview • Expected coagulation parameters…

Slide 1Advances Against Aspergillosis Istanbul, 2012 Anti-fungal therapeutic drug monitoring and azole dose modification Tim Felton Slide 2 Advances Against Aspergillosis…

Slide 1PHARMACOKINETIC DRUG INTERACTIONS Slide 2 DRUGS REMOVED FROM THE MARKET DURING THE 1990s DRUGCATEGORYREASON Astemizoleantihistamineserious metabolic drug intxns Bromfenacanalgesichepatotoxicity…

Slide 1Andrew Gilbert Quality Use of Medicines and Pharmacy Research Centre Sansom Institute University of South Australia Effectiveness of collaborative medicine reviews…

Slide 1Implementing Medication Reconciliation in Long-Term Care O’Connell Date: April 14, 2008 by Bonnie Walker Risk Manager /Patient Safety Advisor Slide 2 Safer Health…

Slide 1ASA - Is there a Primary Prevent Indication in Diabetes? Contemporary Therapeutic Issues in Cardiovascular Disease Saturday, May 8 th, 2010 Patrick Robertson, BSP,…

Folie 1 Nitrattherapie und Nitratresistenz – Implikationen für Diabetes mellitus und KHK Nitrattherapie und Nitratresistenz – Implikationen für Diabetes mellitus und…

Slide 1 Momento científico 04/Setembro/2014 Slide 2 Antipsicóticos Atípicos X riscos Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis…

Slide 1 Diabetes and Cardiovascular Risk La lezione dai grandi studi di intervento Slide 2 Rischio di eventi cardiovascolari a 8 anni nel diabete (Framingham Study) Slide…